Full Press Release Details
CEO Recaps 2022 Achievements & Presents 2023 Catalysts
Mass., Feb. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company
developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO Alon Ben-Noon.
company believes that 2023 presents many opportunities for growth at NeuroSense as topline results are expected in the second half of
the year from its Phase 2b PARADIGM clinical trial in amyotrophic lateral sclerosis (ALS). The PARADIGM protocol is now approved for
enrollment in four countries: Israel, Italy, Canada, and Germany. Based on recently announced positive AD biomarker study results, NeuroSense
plans to commence a Phase 2 study in Alzheimer's disease in the first half of 2023. In the coming weeks, NeuroSense expects to
announce biomarker study results in Parkinson's disease as well.
on this past year, NeuroSense's strong performance in 2022 gives great cause for optimism," stated Alon Ben-Noon. "I
thank our dedicated team, collaborators, shareholders, and the ALS community."
highlights include the following:
Program for Lead Drug Candidate PrimeC
company invites anyone who is interested to watch the video for more on NeuroSense's progress to date and an overview of upcoming
catalysts and milestones: LINK
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering
from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our
time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases
and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies
targeting multiple pathways associated with these diseases.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject
to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding patent applications;
the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical
data for PrimeC; the timing of the report of topline results of PARADIGM; the timing of commencement of our Phase 2 study in Alzheimer's;
the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto;
and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are
based on assumptions as to future events that may not prove to be accurate. Forward looking statements are subject to a number of risks
and uncertainties, including a delay in the reporting of top-line results from our ALS Phase 2b clinical trial, a delay in commencement
of our Phase 2 study in Alzheimer's and a delay in other clinical and regulatory milestones. The future events and trends may not
occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. You
should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and
Exchange Commission on April 14, 2022. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense
Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.
Video: https://youtu.be/sWEmVSDPbDg
